FAYTEC
Roller Compaction and Dry Granulation Technology for the Pharmaceutical Industry
Amgen has announced strong results from a Phase III trial evaluating Vectibix with FOLFIRI chemotherapy, as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). During the trial Vectibix significantly improved progression-free survival in combination with FO
Amgen has announced strong results from a Phase III trial evaluating Vectibix with FOLFIRI chemotherapy, as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC).
During the trial Vectibix significantly improved progression-free survival in combination with FOLFIRI, compared to FOLFIRI alone, in patients with KRAS wild-type mCRC.
The addition of Vectibix had no positive or negative effect on progression-free or overall survival in patients with tumours harbouring activating KRAS mutations.
Amgen vice-president of research and development Roger M Perlmutter said that these results add to the growing body of evidence confirming the utility of KRAS as a predictive biomarker.
“Vectibix has now demonstrated improved progression-free survival in Phase III trials in patients with KRAS wild-type tumours in first- and second-line treatment of metastatic colorectal cancer,” Perlmutter said.
Side effects were as anticipated with irinotecan-based chemotherapy and included skin toxicity, diarrhoea and hypomagnesemia.
Roller Compaction and Dry Granulation Technology for the Pharmaceutical Industry
Distribution of Chemical Products, APIs and Pharmaceutical Excipients
Integrated Analytical Services and Solutions for Safer Pharmaceuticals